Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Differences before and after entering dialysis were statistically significant for almost all drugs/drug classes, except for Insulin, Vitamin D, and Iron chelating agents/Drugs for the treatment of hyperkalaemia and hyperphosphatemia.

Source: Proportions of drug users. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Patients were characterized with respect to sex, age, area of residence, and comorbidities, retrieved from hospital discharge records in the two-year look-back period before the index date, considering any of the six discharge diagnoses reported for each record.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Drug utilization in patients starting haemodialysis with a focus on cardiovascular and antidiabetic medications: an epidemiological study in the Lazio region (Italy), 2016 to 2020

Study design awaiting verification · BMC Nephrology · 2024

Original publication title

Drug utilization in patients starting haemodialysis with a focus on cardiovascular and antidiabetic medications: an epidemiological study in the Lazio region (Italy), 2016 to 2020

Ursula Kirchmayer; Claudia Marino; Sandro Feriozzi; Carlo Massimetti; Micol Manzuoli; Laura Angelici; Anna Maria Bargagli; Silvia Cascini; Antonio Addis; Marina Davoli; Nera Agabiti

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Entering dialysis is associated with increased use of specific drugs and goes along with adaptations of chronic therapies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Entering dialysis is a critical moment in patients’ healthcare journey, and little is known about drug therapy around it. A study funded by the Italian Medicines Agency offered the opportunity to leverage data from the Lazio Regional Dialysis and Transplant Registry (RRDTL) and perform an observational study on drug use patterns before and after initiating chronic dialysis.

Source: Background

Abstract: What methods does the paper describe?

Individuals initiating dialysis in 2016 to 2020 were identified from RRDTL, excluding patients with prior renal transplantation, stopping dialysis early, or dying within 12 months. Use of study drugs, predefined by clinicians, in the two years around the index date was retrieved from the drug claims register and described by semester. For each drug group, proportions of users (min 2 claims in 6 months) by semester, and intensity of treatment in terms of Defined Daily Doses (DDDs) for cardiovascular and antidiabetic agents were compared across semesters, stratifying by sex and age.

Source: Methods

Abstract: Results

In our cohort of 3,882 patients we observed a general increase in drug use after initiating dialysis, with the mean number rising from 5.5 to 6.2. Cardiovascular agents accounted for the highest proportions, along with proton pump inhibitors and antithrombotics over all semesters. Dialysis-specific therapies showed the most evident increase, in particular anti-anaemics (iron 4-fold, erythropoietins almost 2-fold), anti-parathyroids (6-fold), and chelating agents (4-fold). Use of cardiovascular and antidiabetic drugs was characterised by significant variations in terms of patterns and intensity, with some differences between sexes and age groups.

Source: Results

Abstract: Conclusions

Entering dialysis is associated with increased use of specific drugs and goes along with adaptations of chronic therapies.

Source: Conclusions
Authors’ abstract

Background

Entering dialysis is a critical moment in patients’ healthcare journey, and little is known about drug therapy around it. A study funded by the Italian Medicines Agency offered the opportunity to leverage data from the Lazio Regional Dialysis and Transplant Registry (RRDTL) and perform an observational study on drug use patterns before and after initiating chronic dialysis.

Methods

Individuals initiating dialysis in 2016 to 2020 were identified from RRDTL, excluding patients with prior renal transplantation, stopping dialysis early, or dying within 12 months. Use of study drugs, predefined by clinicians, in the two years around the index date was retrieved from the drug claims register and described by semester. For each drug group, proportions of users (min 2 claims in 6 months) by semester, and intensity of treatment in terms of Defined Daily Doses (DDDs) for cardiovascular and antidiabetic agents were compared across semesters, stratifying by sex and age.

Results

In our cohort of 3,882 patients we observed a general increase in drug use after initiating dialysis, with the mean number rising from 5.5 to 6.2. Cardiovascular agents accounted for the highest proportions, along with proton pump inhibitors and antithrombotics over all semesters. Dialysis-specific therapies showed the most evident increase, in particular anti-anaemics (iron 4-fold, erythropoietins almost 2-fold), anti-parathyroids (6-fold), and chelating agents (4-fold). Use of cardiovascular and antidiabetic drugs was characterised by significant variations in terms of patterns and intensity, with some differences between sexes and age groups.

Conclusions

Entering dialysis is associated with increased use of specific drugs and goes along with adaptations of chronic therapies.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12882-024-03539-5.

Publication and source details

Original title: Drug utilization in patients starting haemodialysis with a focus on cardiovascular and antidiabetic medications: an epidemiological study in the Lazio region (Italy), 2016 to 2020

Ursula Kirchmayer; Claudia Marino; Sandro Feriozzi; Carlo Massimetti; Micol Manzuoli; Laura Angelici; Anna Maria Bargagli; Silvia Cascini; Antonio Addis; Marina Davoli; Nera Agabiti

BMC Nephrology · 2024

© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100003197Agenzia Italiana del Farmaco, Ministero della SalutePharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)Pharmacovigilance call 2012-2013-2014 (ETELDIA project)

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:36:23.342385+00:00

DOI: 10.1186/s12882-024-03539-5 · PMC10943891